Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729290 | 0.85 | MEN1 (0.49) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL31111007 | 0.84 | PTPN1 (0.40) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL27287731 | 0.84 | MTNR1A (0.52) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL14420215 | 0.83 | KDM4E (0.44) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL31042998 | 0.82 | KMT2A (0.51) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL965852 | 0.82 | KMT2A (0.51) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL23703592 | 0.82 | KDM4E (0.43) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL2060569 | 0.81 | KDM4E (0.44) | KMT2AMEN1KDM4EALDH1A1TDP1 | |
| SCHEMBL13696433 | 0.81 | SMN1; SMN2 (0.46) | KMT2AKDM4EALDH1A1TDP1L3MBTL1 | |
| SCHEMBL15056307 | 0.81 | KDM4E (0.44) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298135-B1 | BIS-PHENOXY-ETHER LIGANDS FOR GROUP IV POLYOLEFIN CATALYSIS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240158542-A1 | BIS-PHENOXY-ETHER LIGANDS FOR GROUP IV POLYOLEFIN CATALYSIS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-05-16 | — | — | US | disclosed |
| CN-117580836-A | Pyrimidine ring structure derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4298135-A1 | BIS-PHENOXY-ETHER LIGANDS FOR GROUP IV POLYOLEFIN CATALYSIS | Dow Global Technologies LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-116897168-A | Bis-phenoxy-ether ligands for Group IV polyolefin catalysis | 陶氏环球技术有限责任公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022268209-A1 | DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF | 四川汇宇制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022268209-A1 | DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF | 四川汇宇制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022183005-A1 | BIS-PHENOXY-ETHER LIGANDS FOR GROUP IV POLYOLEFIN CATALYSIS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| CN-105143170-B | For treating the aromatic compounds of pulmonary fibrosis, liver fibrosis, fibrosis of skin and cardiac fibrosis being substituted | 普罗米蒂克医药SMT有限公司 | 2019-11-08 | — | — | CN | disclosed |
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2794563-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093842-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-06-27 | — | — | WO | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGER1, PTGDR2 | KMT2A 4057/4885MEN1 2511/4885KDM4E 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.